Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies
-
By
-
Chunxiao Gao
-
Ting Zhang
-
Guangyuan Li
-
Weishan Zhang
-
Honglin Chen
-
Diefei Li
-
Jixuan Xu
-
Mengxue Li
-
Ruihong Wang
-
Yamin Xing
-
Jian Zhan
-
Zhentai Ren
-
Xia Xue
-
Wulong Liang
-
Xiangdong Sun
-
Xiaojuan Zhang
-
Xinfeng Liang
-
Hongqiao Zhan
-
Zisen Zhang
-
Xiufeng Chu
-
July 3, 2026
-
Clinical Scorecard: Correction: Strategies to Address Chemoresistance in Esophageal Cancer through Synergistic Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Esophageal Cancer |
| Key Mechanisms | Chemoresistance mechanisms include DNA damage response, immune checkpoint expression, and tumor microenvironment interactions. |
| Target Population | Patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). |
| Care Setting | Oncology and clinical trials. |
Key Highlights
- Chemotherapy is a cornerstone in the management of esophageal cancer.
- Neoadjuvant chemoradiotherapy or chemotherapy enhances surgical resectability.
- CD8+ T cells are functionally impaired in esophageal cancer.
- PARP inhibitors are being explored to enhance the efficacy of DNA-damaging chemotherapy.
- CDK4/6 inhibitors show promise in overcoming cell cycle-related chemoresistance.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of esophageal cancer should include histopathological confirmation and staging.
Management
- First-line systemic therapy typically involves a fluoropyrimidine plus a platinum agent.
Monitoring & Follow-up
- Regular assessment of treatment response and side effects is essential.
Risks
- Chemoresistance can lead to treatment failure and disease progression.
Patient & Prescribing Data
Patients with advanced esophageal cancer.
Combination therapies are being investigated to overcome chemoresistance.
Clinical Best Practices
- Utilize neoadjuvant therapies to improve surgical outcomes.
- Consider immune checkpoint inhibitors in treatment regimens.
- Incorporate clinical trials for novel therapies targeting chemoresistance.
Related Resources & Content
